Kura Oncology, Inc. (KURA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	77.2M	67.5M	53.9M	—	—
Cost of Revenue	4.1M	57.0K	—	849.0K	—
Gross Profit	73.2M	67.4M	53.9M	(849.0K)	—
Operating Expenses
R&D Expense	259.5M	251.1M	170.0M	115.2M	92.8M
SG&A Expense	134.9M	120.0M	77.1M	50.6M	47.1M
General & Admin Expense	103.7M	120.0M	77.1M	50.6M	47.1M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(3.2M)	—	—	(849.0K)	—
Total Operating Expenses	391.2M	371.1M	247.1M	165.0M	139.9M
Cost and Expenses	395.3M	371.1M	247.1M	165.8M	139.9M
Operating Income (EBIT)	(318.1M)	(303.6M)	(193.2M)	(165.8M)	(139.9M)
Non-Operating
Interest Income	17.8M	26.8M	22.8M	14.7M	4.3M
Interest Expense	1.4M	1.5M	1.6M	1.5M	229.0K
Net Interest Income	16.4M	25.3M	21.2M	13.2M	4.0M
Other Non-Op Income/Expense	21.4M	25.3M	21.2M	13.2M	4.0M
Non-Operating Income (excl Interest)	(22.4M)	(26.8M)	(22.8M)	(14.7M)	(4.3M)
EBT (Pre-Tax Income)	(296.7M)	(278.4M)	(172.0M)	(152.6M)	(135.8M)
Income Tax Expense	84.0K	297.0K	2.0M	—	—
Bottom Line
Net Income	(296.8M)	(278.7M)	(174.0M)	(152.6M)	(135.8M)
Earnings from Cont. Ops	(296.8M)	(278.7M)	(174.0M)	(152.6M)	(135.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(296.8M)	(278.7M)	(174.0M)	(152.6M)	(135.8M)
Per Share
Basic EPS	($3.37)	($3.18)	($2.02)	($2.08)	($2.03)
Diluted EPS	($3.37)	($3.18)	($2.02)	($2.08)	($2.03)
Revenue Per Share	$0.87	$0.77	$0.63	$0.00	$0.00
Shares
Basic Shares Outstanding	88.9M	87.7M	86.2M	73.2M	67.0M
Diluted Shares Outstanding	88.9M	87.7M	86.2M	73.2M	67.0M
Profitability Metrics
EBITDA	(292.4M)	(275.8M)	(169.5M)	(150.2M)	(134.9M)
D&A	3.3M	1.0M	848.0K	849.0K	759.0K
EBIT	(295.7M)	(276.9M)	(170.3M)	(151.1M)	(135.6M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026